Literature DB >> 24860142

Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease.

Ashley R Winslow1, Simon Moussaud2, Liya Zhu1, Kathryn L Post, Katherine L Post1, Dennis W Dickson2, Oksana Berezovska3, Pamela J McLean4.   

Abstract

A growing number of PSEN1 mutations have been associated with dementia with Lewy bodies and familial Alzheimer's disease with concomitant α-synuclein pathology. The objective of this study was to determine if PSEN1 plays a direct role in the development of α-synuclein pathology in these diseases. Using mass spectrometry, immunoelectron microscopy and fluorescence lifetime image microscopy based on Forster resonance energy transfer (FLIM-FRET) we identified α-synuclein as a novel interactor of PSEN1 in wild-type mouse brain tissue. The interaction of α-synuclein with PSEN1 was detected in post-mortem brain tissue from cognitively normal cases and was significantly increased in tissue from cases with dementia with Lewy bodies and familial Alzheimer's disease associated with known PSEN1 mutations. We confirmed an increased interaction of PSEN1 and α-synuclein in cell lines expressing well characterized familial Alzheimer's disease PSEN1 mutations, L166P and delta exon 9, and demonstrated that PSEN1 mutations associate with increased membrane association and accumulation of α-synuclein. Our data provides evidence of a molecular interaction of PSEN1 and α-synuclein that may explain the clinical and pathophysiological overlap seen in synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and some forms of Alzheimer's disease.
© The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer’s disease; Lewy body; Parkinson’s disease; ageing; dementia; presenilin; α-synuclein

Mesh:

Substances:

Year:  2014        PMID: 24860142      PMCID: PMC4065023          DOI: 10.1093/brain/awu119

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  50 in total

1.  Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation.

Authors:  Alberto Lleó; Oksana Berezovska; Lauren Herl; Susan Raju; Amy Deng; Brian J Bacskai; Matthew P Frosch; Michael Irizarry; Bradley T Hyman
Journal:  Nat Med       Date:  2004-09-26       Impact factor: 53.440

2.  Familial aggregation of dementia with Lewy bodies.

Authors:  Angela Nervi; Christiane Reitz; Ming-Xin Tang; Vincent Santana; Angel Piriz; Dolly Reyes; Rafael Lantigua; Martin Medrano; Ivonne Z Jiménez-Velázquez; Joseph H Lee; Richard Mayeux
Journal:  Arch Neurol       Date:  2011-01

3.  Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein.

Authors:  Oksana Berezovska; Alberto Lleo; Lauren D Herl; Matthew P Frosch; Edward A Stern; Brian J Bacskai; Bradley T Hyman
Journal:  J Neurosci       Date:  2005-03-16       Impact factor: 6.167

4.  Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form.

Authors:  He-Jin Lee; Chan Choi; Seung-Jae Lee
Journal:  J Biol Chem       Date:  2001-10-25       Impact factor: 5.157

5.  Autophagy impairment stimulates PS1 expression and gamma-secretase activity.

Authors:  Kazunori Ohta; Akihito Mizuno; Masashi Ueda; Shimo Li; Yoshihiro Suzuki; Yoko Hida; Yoshika Hayakawa-Yano; Masanori Itoh; Eri Ohta; Masuko Kobori; Toshiyuki Nakagawa
Journal:  Autophagy       Date:  2010-04-11       Impact factor: 16.016

6.  Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity.

Authors:  Preeti Putcha; Karin M Danzer; Lisa R Kranich; Anisa Scott; Melanie Silinski; Sarah Mabbett; Carol D Hicks; James M Veal; Paul M Steed; Bradley T Hyman; Pamela J McLean
Journal:  J Pharmacol Exp Ther       Date:  2009-11-24       Impact factor: 4.030

7.  A cDNA library functional screening strategy based on fluorescent protein complementation assays to identify novel components of signaling pathways.

Authors:  Ingrid Remy; Stephen W Michnick
Journal:  Methods       Date:  2004-04       Impact factor: 3.608

8.  Enrichment of presenilin 1 peptides in neuronal large dense-core and somatodendritic clathrin-coated vesicles.

Authors:  S Efthimiopoulos; E Floor; A Georgakopoulos; J Shioi; W Cui; S Yasothornsrikul; V Y Hook; T Wisniewski; L Buee; N K Robakis
Journal:  J Neurochem       Date:  1998-12       Impact factor: 5.372

9.  Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.

Authors:  Jacqueline Burré; Manu Sharma; Theodoros Tsetsenis; Vladimir Buchman; Mark R Etherton; Thomas C Südhof
Journal:  Science       Date:  2010-08-26       Impact factor: 47.728

10.  Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology.

Authors:  Megan E Larson; Mathew A Sherman; Susan Greimel; Michael Kuskowski; Julie A Schneider; David A Bennett; Sylvain E Lesné
Journal:  J Neurosci       Date:  2012-07-25       Impact factor: 6.167

View more
  18 in total

Review 1.  Genetics and underlying pathology of dementia.

Authors:  Beata Ferencz; Lotte Gerritsen
Journal:  Neuropsychol Rev       Date:  2015-01-08       Impact factor: 7.444

Review 2.  Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy.

Authors:  E Valera; G Monzio Compagnoni; E Masliah
Journal:  Neuropathol Appl Neurobiol       Date:  2016-02       Impact factor: 8.090

Review 3.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

4.  Diffuse Lewy Body Disease and Alzheimer Disease: Neuropathologic Phenotype Associated With the PSEN1 p.A396T Mutation.

Authors:  Dibson D Gondim; Adrian Oblak; Jill R Murrell; Rose Richardson; Francine Epperson; Owen A Ross; Bernardino Ghetti
Journal:  J Neuropathol Exp Neurol       Date:  2019-07-01       Impact factor: 3.685

Review 5.  Pathogenesis of age-related HIV neurodegeneration.

Authors:  Miroslaw Mack Mackiewicz; Cassia Overk; Cristian L Achim; Eliezer Masliah
Journal:  J Neurovirol       Date:  2019-02-21       Impact factor: 2.643

Review 6.  Lewy Body Dementias: Controversies and Drug Development.

Authors:  Shannon Y Chiu; Dawn Bowers; Melissa J Armstrong
Journal:  Neurotherapeutics       Date:  2021-12-02       Impact factor: 6.088

Review 7.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

8.  Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model.

Authors:  Brian Spencer; Paula A Desplats; Cassia R Overk; Elvira Valera-Martin; Robert A Rissman; Chengbiao Wu; Michael Mante; Anthony Adame; Jazmin Florio; Edward Rockenstein; Eliezer Masliah
Journal:  J Neurosci       Date:  2016-07-27       Impact factor: 6.167

9.  A possible relationship between telomere length and markers of neurodegeneration in rat brain after welding fume inhalation exposure.

Authors:  Mohammad Shoeb; Gul M Mustafa; Vamsi K Kodali; Kelly Smith; Katherine A Roach; Gregory Boyce; Terence Meighan; Jenny R Roberts; Aaron Erdely; James M Antonini
Journal:  Environ Res       Date:  2019-11-05       Impact factor: 6.498

Review 10.  Proteomics in Traditional Chinese Medicine with an Emphasis on Alzheimer's Disease.

Authors:  Yanuar Alan Sulistio; Klaus Heese
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-18       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.